Capital DailyCapital Daily
Finance

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Published June 11, 2026 · Category: Finance

Overview

Among healthcare stocks, Bristol Myers Squibb (NYSE: BMY) has built a solid track record of dividend growth. The pharmaceutical company has increased its quarterly dividends during each of the past 18 years.

The company faces patent expirations for Eliquis and other flagship drugs, raising concerns that it can maintain (let alone grow) the dividend. Resolving the company's "patent cliff" remains a work in progress, but there is one important number that offers reassurances about this blue chip dividend stock's growth prospects.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.